Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Lee (Yongin, Republic of Korea), D. Bae (Yongin, Republic of Korea), M. Cho (Yongin, Republic of Korea), S. Shin (Yongin, Republic of Korea), J. Kim (Yongin, Republic of Korea), J. Lee (Yongin, Republic of Korea), S. Kang (Yongin, Republic of Korea), J. Jung (Yongin, Republic of Korea), H. Koo (Yongin, Republic of Korea), J. Park (Yongin, Republic of Korea). A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease. 4241

Member's Comments

No comment yet.

Related content which might interest you: Local Administration of Targeted Liposomes Loaded with Everolimus for Interstitial Lung Disease in Systemic Sclerosis Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Diffuse Pulmonary Non-Amyloid Light-Chain Deposition Disease: Phenotypes and Outcome Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Physical Training Improves Lung Function and Mechanics and Pulmonary and Systemic Immune Response in Eutrophic Women Source: Virtual Congress 2020 – Novel insights into exercise training Year: 2020 Oral presentation: A New Target and Novel Agent to Prevent Acute Lung Injury Source: Lung Science Conference 2014 - Lung Inflammation and Immunity Year: 2014 Does a Tailored Intervention to Promote Adherence in Patients with Chronic Lung Disease Affect Exacerbations? Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019 Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Utility of Lung Ultrasound in Interstitial Lung Disease - A Paradigm Shift Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Late Breaking Abstract - TriOptimize VIII – Improvement of Lung Function with Extrafine Single Inhaler Triple Therapy – Analysis of Response Patterns by Prior Treatment from a Real-World Study. Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Resistance Training Alone Improves Lung Inflammation and Respiratory Muscle Strenght but not Lung Function and Mechanics in Mid-Age Women Source: Virtual Congress 2020 – Novel insights into exercise training Year: 2020 Molecular Markers of Telomere Dysfunction and Senescence are Common Findings in the Usual Interstitial Pneumonia Pattern of Lung Fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 High Intensity Resistance Training Improves Respiratory, Peripheral, Quality of Life and Emotional Response in Elderly with Parkinson Disease Source: International Congress 2017 – Best abstracts in pulmonary rehabilitation in patients with chronic lung diseases Year: 2017 Effect of Antifibrotic Therapies in Patients with Interstitial Pneumonia with Autoimmune Features Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Smart Watch-based Coaching with Tiotropium and Olodaterol Ameliorates Physical Activity in Chronic Obstructive Pulmonary Disease Patients Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Aerobic and Weightlifting Training Improves Lung Function and Mechanics and Pulmonary and Systemic Immune Response in Overweight Women Source: Virtual Congress 2020 – Novel insights into exercise training Year: 2020 Comprehensive Metabolic Profiling Reveals Metabolic Perturbances and Identifies Potential Biomarkers in Chronic Persistent Bronchial Asthma with Different Levels of Eosinophilia Percentage Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Aerobic Training Improves Pulmonary and Systemic Inflammatory and Fibrotic Response in Asthmatics Source: Virtual Congress 2021 – A multidisciplinary approach to the management of chronic respiratory diseases Year: 2021 The Frequency of Small Airway Dysfunction and Its Relationship with Disease Control in Chronic Airway Diseases Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases Year: 2021